The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion
- PMID: 7720176
- DOI: 10.1007/BF00685732
The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion
Abstract
It has often been reported that the oxazaphosphorines ifosfamide and cyclophosphamide induce their own metabolism. This phenomenon was studied in 21 paediatric patients over 35 courses of therapy. All patients received 9 gm-2 of ifosfamide as a continuous infusion over 72 h. Plasma concentrations of parent drug and of the major metabolite in plasma, 3-dechloroethylifosfamide (3DC) were determined, using a quantitative thin-layer chromatography (TLC) technique. A one-compartment model was fitted simultaneously to both ifosfamide and 3DC data. The model included a time-dependent clearance term, increasing asymptotically from an initial value to a final induced clearance and characterised by a first-order rate constant. A time lag, before induction of clearance began, was determined empirically. Metabolite kinetics were characterised by an elimination rate constant for the metabolite and a composite parameter comprising a formation clearance, proportional to the time-dependent clearance of parent drug, divided by the volume of distribution of the metabolite. Thus, the parameters to estimate were the volume of distribution of parent drug (V), initial clearance (Cli), final clearance (Cls), the rate constant for changing clearance (Kc), the elimination rate constant for the metabolite (Km) and Vm/fm, the metabolite volume of distribution divided by the fractional clearance to 3DC. The model of drug and metabolite kinetics produced a good fit to the data in 22 of 31 courses. In a further 4 courses an auto-inductive model for parent drug alone could be used. In the remaining courses, auto-induction could be demonstrated, but there were insufficient data to fit the model. For some patients this was due to a long time lag (up to 54 h) relative to the infusion time. The time lag varied from 6 to 54 (median, 12)h and values for the other parameters were Cli, 3.27 +/- 2.52 lh-1 m-2, Cls, 7.50 +/- 3.03 lh-1 m-2, V, 22.0 +/- 11.0 1 m-2, Kc, 0.086 +/- 0.074 h-1; Km, 0.159 +/- 0.077 h-1 and Vm/fm, 104 +/- 82 1m-2. The values of Kc correspond to a half-life of change in clearance ranging from 2 to 157 h, although for the majority of the patients the half-life was less than 7 h and a new steady-state level was achieved during the 72 h infusion period. This model provides insight into the time course of enzyme induction during ifosfamide administration, which may continue for up to 10 days in some protocols.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Metabolism and pharmacokinetics of oxazaphosphorines.Clin Pharmacokinet. 2000 Apr;38(4):291-304. doi: 10.2165/00003088-200038040-00001. Clin Pharmacokinet. 2000. PMID: 10803453 Review.
-
Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.Cancer Res. 1993 Aug 15;53(16):3758-64. Cancer Res. 1993. PMID: 8339288
-
Pharmacokinetic modelling of ifosfamide administered by continuous infusion on 5 days at the dose of 6 g/m2.Anticancer Res. 1999 Jan-Feb;19(1B):837-42. Anticancer Res. 1999. PMID: 10216502
-
Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.Clin Pharmacokinet. 2001;40(8):615-25. doi: 10.2165/00003088-200140080-00005. Clin Pharmacokinet. 2001. PMID: 11523727
-
Ifosfamide clinical pharmacokinetics.Clin Pharmacokinet. 1994 Jun;26(6):439-56. doi: 10.2165/00003088-199426060-00003. Clin Pharmacokinet. 1994. PMID: 8070218 Review.
Cited by
-
A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.Br J Clin Pharmacol. 1999 Nov;48(5):669-77. doi: 10.1046/j.1365-2125.1999.00090.x. Br J Clin Pharmacol. 1999. PMID: 10594468 Free PMC article. Clinical Trial.
-
A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS-114.CPT Pharmacometrics Syst Pharmacol. 2022 May;11(5):604-615. doi: 10.1002/psp4.12747. Epub 2021 Dec 23. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 34951129 Free PMC article.
-
A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat.Pharm Res. 2006 Mar;23(3):521-32. doi: 10.1007/s11095-005-9571-z. Epub 2006 Mar 15. Pharm Res. 2006. PMID: 16525862
-
Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.Br J Clin Pharmacol. 1999 Jul;48(1):43-52. doi: 10.1046/j.1365-2125.1999.00974.x. Br J Clin Pharmacol. 1999. PMID: 10383559 Free PMC article. Clinical Trial.
-
Metabolism and pharmacokinetics of oxazaphosphorines.Clin Pharmacokinet. 2000 Apr;38(4):291-304. doi: 10.2165/00003088-200038040-00001. Clin Pharmacokinet. 2000. PMID: 10803453 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous